A 52-Week, Phase 3, Double-blind, Placebo-controlled, Randomized Study of the Efficacy and Safety of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs Lixivaptan (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Registrational; Therapeutic Use
- Sponsors Palladio Biosciences
- 05 Nov 2019 According to Palladio Biosciences media release, the clinical design and main elements of this study will be presented in two poster sessions during the American Society of Nephrologys Kidney Week 2019, to be held in Washington, D.C. on November 7-10.
- 19 Aug 2019 Status changed from planning to not yet recruiting.
- 14 May 2018 New trial record